Abstract
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.
| Original language | English |
|---|---|
| Pages (from-to) | 181-191 |
| Number of pages | 11 |
| Journal | Journal of Pathology and Translational Medicine |
| Volume | 55 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2021 |
Bibliographical note
Publisher Copyright:© 2021 The Korean Society of Pathologists/The Korean Society for Cytopathology
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Biomarker
- Carcinoma
- Consensus
- Non-small-cell lung
- Precision medicine
Fingerprint
Dive into the research topics of 'Molecular biomarker testing for non-small cell lung cancer: Consensus statement of the Korean Cardiopulmonary Pathology Study Group'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver